Medical Market Report

Global RNA Drugs Market By Type (siRNA, ASO, miRNA, and Nucleic Acid Aptamers), By Application (Cancer, Diabetes, Tuberculosis, and Cardiovascular Diseases), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029

  • 137363
  • 18-Dec
  • PDF/PPT/Word
  • ★ ★ ★ ★ ★
    ★ ★ ★ ★ ★
  • Report Details

    The report on RNA Drugs Market offers in-depth analysis of market trends, drivers, restraints, opportunities etc. Along with qualitative information, this report includes the quantitative analysis of various segments in terms of market share, growth, opportunity analysis, market value, etc. for the forecast years. The global rna drugs market is segmented on the basis of Type, Application, and geography.

    The Global RNA Drugs market is estimated to be US$ XX.X Mn in 2019 and is projected to increase significantly at a CAGR of x.x% from 2020 to 2028.

    RNA Drugs Market Scope:

    By type, the market is segmented into siRNA, ASO, miRNA, and Nucleic Acid Aptamers. By Application, the market is divided into Cancer, Diabetes, Tuberculosis, and Cardiovascular Diseases.
    Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include Pfizer, Roche, Sanofi-Aventis, Abbott Laboratories, Arrowhead Pharmaceuticals, Benitec Biopharma, Benitec Biopharma, Dicerna, Gradalis, Quark, RXi, Senesco, Silence Therapeutics, Silenseed, Tekmira, and Alnylam Pharmaceuticals.

    Key Market Segments

    Type

    siRNA
    ASO
    miRNA
    Nucleic Acid Aptamers

    Application

    Cancer
    Diabetes
    Tuberculosis
    Cardiovascular Diseases

    Key Market Players included in the report:

    Pfizer
    Roche
    Sanofi-Aventis
    Abbott Laboratories
    Arrowhead Pharmaceuticals
    Benitec Biopharma
    Benitec Biopharma
    Dicerna
    Gradalis
    Quark
    RXi
    Senesco
    Silence Therapeutics
    Silenseed
    Tekmira
    Alnylam Pharmaceuticals

    Reasons to Get this Report:

    In an insight outlook, this research report has dedicated to several quantities of analysis – industry research (global industry trends) and RNA Drugs Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of RNA Drugs Market; high-growth regions; and market drivers, restraints, and also market chances.
    The analysis covers RNA Drugs Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global RNA Drugs Market across sections such as also Application and representatives.
    Additionally, the analysis also has a comprehensive review of the crucial players on the RNA Drugs Market together side their company profiles, SWOT analysis, latest advancements, and business plans.

    The analysis objectives of the report are:

    To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
    To know the RNA Drugs Market by pinpointing its many subsegments.
    To profile the important players and analyze their growth plans.
    To endeavor the amount and value of RNA Drugs sub-markets, depending on key regions (various vital states).
    To analyze RNA Drugs Market concerning growth trends, prospects, and also their participation in the entire sector.
    To examine and study the RNA Drugs Market size (volume & value) from the company, essential regions/countries, products, and Application, background information from 2014 to 2019, and also prediction to 2028.
    Primary worldwide RNA Drugs Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
    To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market.

  • Table Of Content 
    1. RNA Drugs Market Introduction
    

    1.1. Definition
    
1.2. Taxonomy
    
1.3. Research Scope2. Executive Summary
    

      2.1. Key Findings by Major Segments
    
  2.2. Top strategies by Major Players3. Global RNA Drugs Market Overview
    

    3.1. RNA Drugs Market Dynamics
    

        3.1.1. Drivers
    
    3.1.2. Opportunities
    
    3.1.3. Restraints
    
    3.1.4. Challenges  3.2. PESTLE Analysis
    
  3.3. Opportunity Map Analysis
    
  3.4. PORTER’S Five Forces Analysis
    
  3.5. Market Competition Scenario Analysis
    
  3.6. Product Life Cycle Analysis
    
  3.7. Opportunity Orbits
    
  3.8. Production Analysis by Region/Company
    
  3.9. Industry chain Analysis
    
  3.10. Marketing Strategy4. Global RNA Drugs Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
    

      4.1. Global RNA Drugs Market Analysis by Type: Introduction
    
  4.2. Market Size and Forecast by Region
    
  4.3. siRNA
    

      4.4. ASO
    

      4.5. miRNA
    

      4.6. Nucleic Acid Aptamers5. Global RNA Drugs Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
    

      5.1. Global RNA Drugs Market Analysis by Application: Introduction
    
  5.2. Market Size and Forecast by Region
    
  5.3. Cancer
    

      5.4. Diabetes
    

      5.5. Tuberculosis
    

      5.6. Cardiovascular Diseases6. Global RNA Drugs Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
    

      6.1. North America
    

        6.1.1. North America RNA Drugs Market: Regional Trend Analysis
    

         6.1.1.1. US
    
     6.1.1.2. Canada
    
     6.1.1.3. Mexico
    

      6.2.1. Europe
    

        6.2.1. Europe RNA Drugs Market: Regional Trend Analysis
    

         6.2.1.1. Germany
    
     6.2.1.2. France
    
     6.2.1.3. UK
    
     6.2.1.4. Russia
    
     6.2.1.5. Italy
    
     6.2.1.6. Spain
    
     6.2.1.7. Rest of Europe
    

      6.3. Asia-Pacific
    

        6.3.1. Asia-Pacific RNA Drugs Market: Regional Trend Analysis
    

         6.3.1.1. China
    
     6.3.1.2. Japan
    
     6.3.1.3. Korea
    
     6.3.1.4. India
    
     6.3.1.5. Rest of Asia-Pacific
    

      6.4. Latin America
    

        6.4.1. Latin America RNA Drugs Market: Regional Trend Analysis
    

         6.4.1.1. Brazil
    
     6.4.1.2. Argentina
    
     6.4.1.3. Rest of Latin America
    

      6.5. Middle East and Africa
    

        6.5.1. Middle East and Africa RNA Drugs Market: Regional Trend Analysis
    

         6.5.1.1. GCC
    
     6.5.1.2. South Africa
    
     6.5.1.3. Israel
    
     6.5.1.4. Rest of MEA
    
7. Global RNA Drugs Market Competitive Landscape, Market Share Analysis, and Company Profiles
    

      7.1. Market Share Analysis
    
  7.2. Company Profiles
    
  7.3. Pfizer
    

        7.3.1. Company Overview
    
    7.3.2. Financial Highlights
    
    7.3.3. Product Portfolio
    
    7.3.4. SWOT Analysis
    
    7.3.5. Key Strategies and Developments  7.4. Roche
    

        7.4.1. Company Overview
    
    7.4.2. Financial Highlights
    
    7.4.3. Product Portfolio
    
    7.4.4. SWOT Analysis
    
    7.4.5. Key Strategies and Developments  7.5. Sanofi-Aventis
    

        7.5.1. Company Overview
    
    7.5.2. Financial Highlights
    
    7.5.3. Product Portfolio
    
    7.5.4. SWOT Analysis
    
    7.5.5. Key Strategies and Developments  7.6. Abbott Laboratories
    

        7.6.1. Company Overview
    
    7.6.2. Financial Highlights
    
    7.6.3. Product Portfolio
    
    7.6.4. SWOT Analysis
    
    7.6.5. Key Strategies and Developments  7.7. Arrowhead Pharmaceuticals
    

        7.7.1. Company Overview
    
    7.7.2. Financial Highlights
    
    7.7.3. Product Portfolio
    
    7.7.4. SWOT Analysis
    
    7.7.5. Key Strategies and Developments  7.8. Benitec Biopharma
    

        7.8.1. Company Overview
    
    7.8.2. Financial Highlights
    
    7.8.3. Product Portfolio
    
    7.8.4. SWOT Analysis
    
    7.8.5. Key Strategies and Developments  7.9. Benitec Biopharma
    

        7.9.1. Company Overview
    
    7.9.2. Financial Highlights
    
    7.9.3. Product Portfolio
    
    7.9.4. SWOT Analysis
    
    7.9.5. Key Strategies and Developments  7.10. Dicerna
    

        7.10.1. Company Overview
    
    7.10.2. Financial Highlights
    
    7.10.3. Product Portfolio
    
    7.10.4. SWOT Analysis
    
    7.10.5. Key Strategies and Developments  7.11. Gradalis
    

        7.11.1. Company Overview
    
    7.11.2. Financial Highlights
    
    7.11.3. Product Portfolio
    
    7.11.4. SWOT Analysis
    
    7.11.5. Key Strategies and Developments  7.12. Quark
    

        7.12.1. Company Overview
    
    7.12.2. Financial Highlights
    
    7.12.3. Product Portfolio
    
    7.12.4. SWOT Analysis
    
    7.12.5. Key Strategies and Developments  7.13. RXi
    

        7.13.1. Company Overview
    
    7.13.2. Financial Highlights
    
    7.13.3. Product Portfolio
    
    7.13.4. SWOT Analysis
    
    7.13.5. Key Strategies and Developments  7.14. Senesco
    

        7.14.1. Company Overview
    
    7.14.2. Financial Highlights
    
    7.14.3. Product Portfolio
    
    7.14.4. SWOT Analysis
    
    7.14.5. Key Strategies and Developments  7.15. Silence Therapeutics
    

        7.15.1. Company Overview
    
    7.15.2. Financial Highlights
    
    7.15.3. Product Portfolio
    
    7.15.4. SWOT Analysis
    
    7.15.5. Key Strategies and Developments  7.16. Silenseed
    

        7.16.1. Company Overview
    
    7.16.2. Financial Highlights
    
    7.16.3. Product Portfolio
    
    7.16.4. SWOT Analysis
    
    7.16.5. Key Strategies and Developments  7.17. Tekmira
    

        7.17.1. Company Overview
    
    7.17.2. Financial Highlights
    
    7.17.3. Product Portfolio
    
    7.17.4. SWOT Analysis
    
    7.17.5. Key Strategies and Developments  7.18. Alnylam Pharmaceuticals
    

        7.18.1. Company Overview
    
    7.18.2. Financial Highlights
    
    7.18.3. Product Portfolio
    
    7.18.4. SWOT Analysis
    
    7.18.5. Key Strategies and Developments
    

    8. Assumptions and Acronyms
    
9. Research Methodology
    
10. Contact
  • Inquiry Before Buying

    Inquiry Form

  • Request Sample

    Request for Sample

Related Reports

Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.